शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
AHCLNSEANLON HEALTHCARE LIMITED· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Fri, 6 Nov, 2026 · 15:59 IST

Q2 FY27 revenue doubles; FY28 revenue target set at INR650-700 crore

Management guided margin improvementMulti-year targets disclosedInvestor Communications View source PDFExplain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Q2 FY27 revenue rose 102.3% year on year to INR105.61 crore. EBITDA increased 84.1% to INR25.24 crore, profit after tax rose 84.4% to INR17.18 crore, and EBITDA margin improved over 600 basis points sequentially to 23.9%. Management targets INR380-400 crore revenue in FY27 and INR650-700 crore in FY28, with FY28 EBITDA margin of 25%-27%.

Likely market impact

Strong growth and margin recovery support the outlook, but planned capacity expansion and fund-raising add execution risk.